OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, September 17, 2008

Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer



Modification of risk for subsequent cancer after f...[Breast Cancer Res Treat. 2008] - PubMed Result

Breast Cancer Res Treat. 2008 Sep;111(1):165-9. Epub 2007 Sep 27.Click here to read Links

Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. k.hemminki@dkfz.de

An increased risk of second primary cancers may depend on many reasons, including therapy for the first cancer and heritable causation. Population level data are not available exploring the risks of subsequent cancers after breast cancer considering a familial history of breast cancers. We used the nation-wide Swedish Family-Cancer Database to investigate such risks, based on 43,398 first invasive female breast cancers. Standardized incidence ratios (SIRs) were calculated for the second cancer after breast cancer using rates for first cancer as a reference. Many cancers at discordant sites were increased after breast cancer. SIRs for subsequent neoplasms in women who had a family history of breast cancer were increased for ovarian (2.0) and endometrial (1.8) cancers and for acute lymphoid leukemia (12.7) and myelofibrosis (9.4). The data suggest that the familial aggregation of breast and endometrial cancers may be explained by yet unidentified heritable causes. The remarkably high risks for second acute lymphoid leukemia and myelofibrosis, both characterized by chromosomal aberrations, in women with a family history of breast cancer may signal heritable defects in the ability to process DNA damage caused by ionizing radiation and chemotherapy.

Spontaneous nasal septal perforation with antiangiogenic Bevacizumab (Avastin) therapy



Spontaneous nasal septal perforation with antiangi...[Laryngoscope. 2008] - PubMed Result

Tuesday, September 16, 2008

2008 September: ESSO conference abstracts (EJSO - the Journal of Cancer surgery www.ejso.com)



binarydata.aspx (application/pdf Object)

Lymphadenectomy Improves 5-Year Survival Rates in Ovarian Cancer Patients: Presented at ESSO



"Since there might be some overlap between performing radical surgery and performing lymphadenectomy, maximal cytoreduction should remain the main objective in ovarian cancer surgery," Dr. Bergzoll concluded.


[Presentation title: The Therapeutic Role of Lymph Node Resection in Ovarian Cancer: Analysis of the Surveillance, Epidemiology, and End Results Database. Abstract 152]

2008 OCNA award winners: Carolyn Benivegna and Karen Mason



OCNA 2008 Award Winners! CONGRATULATIONS!

Cindy Melancon Spirit of Survivorship Award

Hailing from Novi, Michigan, Carolyn Benivegna will be this year’s recipient in honor of her persistent advocacy for promoting awareness for ovarian cancer. Carolyn is an ovarian cancer survivor and the founder of the Ovarian Cancer Alliance of Florida-Gulf Coast. She then moved to Michigan when she made a great impact by working with Governor Jennifer Granholm to declare September as Ovarian Cancer Awareness Month. Carolyn and her husband were also recognized by The Henry P. Tappan Society from the University of Michigan for establishing an endowed Ovarian Cancer Research Fund at UM.



The Voice for Ovarian Cancer Research Award

Taking the trip from Woodbury, NJ will be Karen Mason. After being diagnosed at the age of 49, she quickly discovered that getting involved in the ovarian cancer community was a great coping mechanism. Last Fall Karen was invited to be a member of the Dept of Defense’s Integration Panel where proposals are chosen for funding by the Department of Defense’s Ovarian Cancer Research Program. She also serves as a patient advocate for the Fox Chase Cancer Center ovarian SPORE as a full participating member of their Institutional Review Board evaluating consent forms for clinical trials. Karen is continually involved with NED (no evidence of disease) and is a part-time ICU nurse, wife and mother of two sons.

Level and direction of hope in cancer patients: an...[Support Care Cancer. 2008] - PubMed Result



Level and direction of hope in cancer patients: an...[Support Care Cancer. 2008] - PubMed Result

Pancreatic Resection of Isolated Metastases from N...[Ann Surg Oncol. 2008] - PubMed Result



Pancreatic Resection of Isolated Metastases from N...[Ann Surg Oncol. 2008] - PubMed Result

Combining a symptoms index with CA 125 to improve ...[Cancer. 2008] - PubMed Result



Combining a symptoms index with CA 125 to improve ...[Cancer. 2008] - PubMed Result

Survivorship: Next Steps to Take | Cancer.Net



Survivorship: Next Steps to Take | Cancer.Net

Informal Caregivers - Canadian Hospice Palliative Care Association



Informal Caregivers

Canadian Hospice Palliative Care Association



Home Page

Health System Facts - Percent of population that rates medical care received as very good or excellent, Ontario and by country, 2007



Health System Facts - Percent of population that rates medical care received as very good or excellent, Ontario and by country, 2007

Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study -- Havrilesky et al. 26 (25)



Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study -- Havrilesky et al. 26 (25)

BMJ Evidence Updates



BMJ Evidence Updates

Prognostic implication of endometriosis in clear c...[Gynecol Oncol. 2008] - PubMed Result



Prognostic implication of endometriosis in clear c...[Gynecol Oncol. 2008] - PubMed Result

Therapy-related myeloid leukemia. [Semin Oncol. 2008] - PubMed Result



Therapy-related myeloid leukemia. [Semin Oncol. 2008] - PubMed Result

Chromosomal instability in fallopian tube precurso...[Gynecol Oncol. 2008] - PubMed Result



Chromosomal instability in fallopian tube precurso...[Gynecol Oncol. 2008] - PubMed Result

abstract: Patient Navigation: State of the art or is it science?



Wiley InterScience :: JOURNALS :: Cancer

JCO.2008 Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception



Progress in Cancer Care: The Hope,
the Hype, and the Gap Between Reality
and Perception
JCO.2008.17.6198v1.pdf (application/pdf Object)

abstract:

JCO Early Release, published online ahead of print Sep 15 2008
Journal of Clinical Oncology, 10.1200/JCO.2008.17.6198


Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception

Leonard B. Saltz

Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY

Ovarian cancer drug trial reveals promising new treatment -Ovarian Cancer news-



Ovarian cancer drug trial reveals promising new treatment -Ovarian Cancer news-

Abstract: Breast vs ovarian cancer cells' molecular profile as a response to treatment with anticancer drugs Cisplatin, Carbo, Doxil, VP15 and Taxol



HighWire Press -- Medline Abstract

The Canadian Press: Hope, confusion in hunt for ovarian cancer tests; FDA watches field closely



The Canadian Press: Hope, confusion in hunt for ovarian cancer tests; FDA watches field closely

Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors.



Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors.

The Trajectory of Psychological Impast in BRCA 1/2 Genetic Testing - Does Time Heal?



HighWire Press -- Medline Abstract

Monday, September 15, 2008

2008 Abstract: Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific



HighWire Press -- Medline Abstract

2008 abstract: The Importance of CA125 Normalization During Neoadjuvant Chemotherapy Followed by Planned Delayed Surgical Debulking in Patients



HighWire Press -- Medline Abstract

2008 Factors influencing the implementation of clinical guidelines for health care professionals: a meta-review



1472-6947-8-38.pdf (application/pdf Object)

Researchers identify cancer-causing gene in many colon cancers



Researchers identify cancer-causing gene in many colon cancers

2008 abstract: Meaning in life assessed with the SMiLE: a comparison between a cancer patient and student sample (abstract)



SpringerLink - Journal Article

Clinical Care Options Oncology - Ovarian Cancer: Expert Recap



Clinical Care Options Oncology - Ovarian Cancer: Expert Recap

Welcome to the PeerView Press Website



Welcome to the PeerView Press Website

Public engagement in setting priorities in health care -- Bruni et al. 179 (1): 15 -- Canadian Medical Association Journal



Public engagement in setting priorities in health care -- Bruni et al. 179 (1): 15 -- Canadian Medical Association Journal

Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? -- Suzuki et al. 19 (7): 1284 -- Annals of Oncology



Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? -- Suzuki et al. 19 (7): 1284 -- Annals of Oncology

The Staging of Cancer: A Retrospective and Prospective Appraisal -- Greene and Sobin 58 (3): 180 -- CA: A Cancer Journal for Clinicians



The Staging of Cancer: A Retrospective and Prospective Appraisal -- Greene and Sobin 58 (3): 180 -- CA: A Cancer Journal for Clinicians

'Futile Care': What to Do When Your Patient Insists on Chemotherapy That Likely Won’t Help: - Cancer Network



'Futile Care': What to Do When Your Patient Insists on Chemotherapy That Likely Won’t Help: - Cancer Network

Don't let the silent killer get you by the ovaries



Don't let the silent killer get you by the ovaries

We Fought Cancer And Cancer Won



We Fought Cancer…And Cancer Won

2008 Current Oncology: Presentations from the Integrating Wellness into Cancer Care Conference



2008

Decision Making in Oncology: A Review of Patient Decision Aids to Support Patient Participation -- Stacey et al. 58 (5): 293 -- CA: A Cancer Journal for Clinicians



Decision Making in Oncology: A Review of Patient Decision Aids to Support Patient Participation -- Stacey et al. 58 (5): 293 -- CA: A Cancer Journal for Clinicians

2008 June (Stein study) ACS's Studies of Cancer Survivors



Stein.pdf (application/pdf Object)

Performance of BRCA1/2 Mutation Prediction Models in Asian Americans -- Kurian et al., 10.1200/JCO.2008.16.8310 -- Journal of Clinical Oncology



Performance of BRCA1/2 Mutation Prediction Models in Asian Americans -- Kurian et al., 10.1200/JCO.2008.16.8310 -- Journal of Clinical Oncology

Subdividing Ovarian and Peritoneal Serous Carcinom...[Am J Surg Pathol. 2008] - PubMed Result



Subdividing Ovarian and Peritoneal Serous Carcinom...[Am J Surg Pathol. 2008] - PubMed Result

A phase 2, randomized, double-blind, placebo-contr...[Gynecol Oncol. 2008] - PubMed Result



A phase 2, randomized, double-blind, placebo-contr...[Gynecol Oncol. 2008] - PubMed Result

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling -- Mullen et al. 6 (1): 93 -- Molecular Cancer Therapeutics



Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling -- Mullen et al. 6 (1): 93 -- Molecular Cancer Therapeutics

Lost In Translation? FDA Believes That LabCorp’s Ovarian Cancer Early Detection Test (OvaSure) Lacks Adequate Clinical Validation « Libby’s H*O*P*E*



Lost In Translation? FDA Believes That LabCorp’s Ovarian Cancer Early Detection Test (OvaSure) Lacks Adequate Clinical Validation « Libby’s H*O*P*E*

advocacy9.pdf (application/pdf Object)



advocacy9.pdf (application/pdf Object)

Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables -- Anderson et al. 26 (24): 3913 -- Journal of Clinical Oncology



Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables -- Anderson et al. 26 (24): 3913 -- Journal of Clinical Oncology

Cancer.Net Podcasts | Cancer.Net



Cancer.Net Podcasts | Cancer.Net

When The Patient Can't Decide: Study Looks At Physician Perspectives On Surrogate Decision-making



When The Patient Can't Decide: Study Looks At Physician Perspectives On Surrogate Decision-making

Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors -- Dal Lago et al., 10.1634/theoncologist.2007-0233 -- The Oncologist



Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors -- Dal Lago et al., 10.1634/theoncologist.2007-0233 -- The Oncologist

Advocating a Treatment, but Denied Access to It | BlueRidgeNow.com | Times-News Online | Hendersonville, NC



Advocating a Treatment, but Denied Access to It | BlueRidgeNow.com | Times-News Online | Hendersonville, NC

Medical News: No Evidence of Benefit for Ovary Removal with Hysterectomy - in OB/GYN, General OB/GYN from MedPage Today



Medical News: No Evidence of Benefit for Ovary Removal with Hysterectomy - in OB/GYN, General OB/GYN from MedPage Today

PLoS Medicine - Next Stop, Don't Block the Doors: Opening Up Access to Clinical Trials Results



PLoS Medicine - Next Stop, Don't Block the Doors: Opening Up Access to Clinical Trials Results

NEJM -- Wellness Programs and Lifestyle Discrimination -- The Legal Limits



short abstract:

NEJM -- Wellness Programs and Lifestyle Discrimination -- The Legal Limits

Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern -- Lyman 4 (3): 114 -- Journal of Oncology Practice



Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern -- Lyman 4 (3): 114 -- Journal of Oncology Practice

Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey -- Field et al. 4 (3): 108 -- Journal of Oncology Practice



Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey -- Field et al. 4 (3): 108 -- Journal of Oncology Practice

Biocompare News - New Cancer Gene Discovered



Biocompare News - New Cancer Gene Discovered

Primary Care Physicians and Oncologists Are Players on the Same Team -- Grunfeld 26 (14): 2246 -- Journal of Clinical Oncology



Primary Care Physicians and Oncologists Are Players on the Same Team -- Grunfeld 26 (14): 2246 -- Journal of Clinical Oncology

Cancer often detected in patients with unprovoked venous thromboembolism - ASCO



Cancer often detected in patients with unprovoked venous thromboembolism - ASCO

Ovarian cancers may begin in fallopian tube- msnbc.com



Ovarian cancers may begin in fallopian tube- msnbc.com

Humour can play an essential role in the most serious healthcare settings



Humour can play an essential role in the most serious healthcare settings

Monday September 15th, 2008: CANO conference presentation - Survivors' Debate: The Past Decade in Ovarian Cancer



Survivors Debate: The Past Decade in Ovarian Cancer

Pamela J. West1, Sandi Pniauskas2, Carolyn Benivegna3. 1Rouge Valley Health System, Toronto,
ON, Canada, 2No Institution - patient, Whitby, ON, Canada, 3No Institution - patient,
Novi, MI, USA.

2008 Inquiry will hear cancer warning



telegraphjournal.com - Inquiry will hear cancer warning

Thursday, July 26, 2007

Survivors Debate: "the Past Decade in Ovarian Cancer"



Carolyn Benivegna and Sandi Pniauskas

contact: Sandi Pniauskas 905 668-0767
email: sandipn@sympatico.ca

further information/registration: http://ovariancancerdebate.blogspot.com

online poll: http://cancerissues.blogspot.com/


Survivors' Debate: “The Past Decade in Ovarian Cancer”

WHAT:
Ovarian cancer survivors, Carolyn Benivegna (U.S.) and Sandi Pniauskas (Canada), announce the first ever Ovarian Cancer Survivors Debate. The two conferences are survivor-led and survivor-organized with debate and discussion surrounding the multitude of issues - the past and the present. Open and lively dialogue will be encouraged.


WHO SHOULD ATTEND:
All cancer survivors/caregivers, healthcare professionals, researchers, pharmacists and the general public are encouraged to attend and participate.


WHERE/
WHEN:



#1: Sheraton Hotel, Novi, MI Sat. October 27th, 2007
#2: Metropolitan Hotel, Toronto, ON Sat. November 3rd, 2007
Time: 10:00 am - 12:30 pm



BACKGROUND:


Ovarian cancer has the highest mortality rate of all gynecologic cancers. Ovarian cancer has no early detection test. The debate and ensuing open forum public discussions will include the specifics of disease-related issues including genetics, access to care and communications. Carolyn Benivegna is a nine year ovarian cancer survivor, a BRCA1 carrier and Founder/Board Member of OCAG-GC. Sandi Pniauskas is an eight ovarian cancer survivor with a genetic predisposition to Lynch Syndrome/Hereditary NonPolyposis Colorectal Cancer and a member of the Cochrane Collaboration. Carolyn and Sandi are energetic, knowledgeable ovarian cancer advocates and activists since the beginning of their journeys.

Ovarian cancer survivors Annamarie DeCarlo and Dr. Yi Pan will co-moderate both events. Bridget Capo (R.N.) and Pamela J. West (R.N.) will provide support and collaborate with Benivegna and Pniauskas in formal publication of the event proceedings.

Sunday, July 15, 2007

Lynch Syndrome - Cancer Prevention with Lynch Syndrome



Sandi's comments: One of the issues that I have is the reference in the article: "If you're a woman with Lynch syndrome, you may want to mention this study to your doctor and get her take on how it might apply to you."

As a generalization, the vast majority of hcps have never heard of the Lynch Syndrome (HNPCC).


Lynch Syndrome - Cancer Prevention with Lynch Syndrome: "If you're a woman with Lynch syndrome, you may want to mention this study to your doctor and get her take on how it might apply to you."

Saturday, July 14, 2007

The quality of the operative report for women with ovarian cancer in Ontario.



The quality of the operative report for women with...[J Obstet Gynaecol Can. 2006] - PubMed Result: "

All: 1

Review: 0
[Click to change filter selection through My NCBI.]


1: J Obstet Gynaecol Can. 2006 Oct;28(10):892-7."

Review:
J Obstet Gynaecol Can. 2006 Oct;28(10):892-7.

The quality of the operative report for women with ovarian cancer in Ontario.
Elit L, Bondy S, Chen Z, Law C, Paszat L.

Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada.

OBJECTIVE: To assess the quality of the operative reports from cases of ovarian cancer surgery in Ontario.

METHODS: We undertook a population cohort study including all newly diagnosed ovarian cancer patients treated initially with surgery from January 1996 to December 1998 in Ontario (n = 1341). We abstracted charts from hospitals and cancer centres. All surgical and pathology notes were abstracted into an ACCESS database.

RESULTS: A total of 1,341 women had surgery as the first step in management of ovarian cancer. A vertical abdominal incision was used in 87.6% of these cases. Peritoneal cytology was obtained in 87.8% of cases overall, but in only 69.5% of stage 1 cases. A description of the ovaries was provided in 85% of reports, of the uterus in 70%, the diaphragm in 53%, the liver in 69%, the pelvic lymph nodes in 10%, and the para-aortic lymph nodes in 41%. In stage 1 cases, the ovaries were assessed histologically in 89% of cases, the uterus in 80%, the omentum in 69%, the peritoneum in 20%, the appendix in 9%, the pelvic lymph nodes in 10%, and the para-aortic lymph nodes in 7%. Frozen section was obtained in half of the stage 1 cases, and the false negative rate for identifying malignancy was 6%. In all, 23% of women received adequate surgical staging for stage 1 disease, and 12% of women with advanced disease had optimal debulking (to less than 1 cm residual disease). There are clear differences between centres with a gynaecologic oncologist on staff and other centres in the adequacy of surgical staging in women with stage 1 disease (chi2 = 60.6, P < 0.0001) and in optimal debulking for advanced disease (chi2 = 39.1, P < 0.0001). In 40% of cases with advanced disease, the amount of residual disease following surgery is not reported.

CONCLUSION: The current approach of dictating operative notes does not provide sufficient detail in a large number of cases; this affects treatment decisions and limits our ability to assess quality indicators for operative care in ovarian cancer. This problem is pervasive but is more significant in centres without a gynaecologic oncologist.

Thursday, July 12, 2007

Magnetic resonance spectroscopy for breast cancer



Magnetic resonance spectroscopy for breast cancer

ScienceDirect - Gynecologic Oncology : Use of systemic therapy in women with recurrent ovarian cancer—Development of a national clinical practice guid



ScienceDirect - Gynecologic Oncology : Use of systemic therapy in women with recurrent ovarian cancer—Development of a national clinical practice guideline

ScienceDirect - Gynecologic Oncology : Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary



ScienceDirect - Gynecologic Oncology : Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer

Editorial but no free text- Gynecologic Oncology : Time for action: A “sea change” in treatment strategies for rare types of epithelial ovarian cancer



ScienceDirect - Gynecologic Oncology : Time for action: A “sea change” in treatment strategies for rare types of epithelial ovarian cancer

ScienceDirect - European Journal of Cancer : Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers



ScienceDirect - European Journal of Cancer : Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers

ScienceDirect - European Journal of Cancer : Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation



ScienceDirect - European Journal of Cancer : Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation

ScienceDirect - Journal of Pain and Symptom Management : Complications at the End of Life in Ovarian Cancer



ScienceDirect - Journal of Pain and Symptom Management : Complications at the End of Life in Ovarian Cancer

ScienceDirect - Gynecologic Oncology : Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube c



ScienceDirect - Gynecologic Oncology : Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer

ScienceDirect - Gynecologic Oncology : Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for



ScienceDirect - Gynecologic Oncology : Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials

ScienceDirect - Gynecologic Oncology : Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: Results and 5-year fo



ScienceDirect - Gynecologic Oncology : Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: Results and 5-year follow-up

ScienceDirect - Gynecologic Oncology : Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer



ScienceDirect - Gynecologic Oncology : Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

ScienceDirect - Fertility and Sterility : Safety of testosterone treatment in postmenopausal women



ScienceDirect - Fertility and Sterility : Safety of testosterone treatment in postmenopausal women

Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients --



Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients -- Vaz et al., 10.1369/jhc.7A7209.2007 -- Journal of Histochemistry and Cytochemistry

Germ Cell Cancer - Survivors of rare ovarian cancer retain fertility....



Germ Cell Cancer - Survivors of rare ovarian cancer retain fertility, have p...

Antisoma, Novartis drug fails in ovarian cancer |- Reuters



Antisoma, Novartis drug fails in ovarian cancer | Breaking City News | Reuters.co.uk

Wednesday, July 04, 2007

Complications at the End of Life in Ovarian Cancer. [J Pain Symptom Manage. 2007] - PubMed Result



Complications at the End of Life in Ovarian Cancer. [J Pain Symptom Manage. 2007] - PubMed Result

J Pain Symptom Manage. 2007 Jun 30; [Epub ahead of print]
Complications at the End of Life in Ovarian Cancer.
Herrinton LJ, Neslund-Dudas C, Rolnick SJ, Hornbrook MC, Bachman DJ, Darbinian JA, Jackson JM, Coughlin SS.

Division of Research (L.J.H., J.A.D.), Kaiser Permanente Northern California, Oakland, California; Henry Ford Health Systems (C.N.-D.), Detroit, Michigan; HealthPartners Research Foundation (S.J.R., J.M.J.), Minneapolis, Minnesota; Center for Health Research, Northwest/Hawaii (M.C.H., D.J.B.), Kaiser Permanente Northwest, Portland, Oregon; and Division of Cancer Prevention and Control (S.S.C.), United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Women dying of ovarian cancer vary considerably in their complications and in the types of health care they receive. The objective of this study was to describe the complications of ovarian cancer, other than pain, and their treatment at the end of life. This study used a cohort of 421 enrollees in three nonprofit managed-care organizations who died with ovarian cancer during 1995-2000. Data were collected from abstraction of paper and electronic medical records. Proportions of women experiencing complications and undergoing treatments were calculated. Logistic regression was used to evaluate the association of patient characteristics with the probability of receiving an intervention for complications. The most common complications recorded in the medical record were fatigue or weakness (75%), nausea or vomiting (71%), constipation (49%), edema of the extremities (44%), and anemia (34%). The prevalence of major complications was as follows: ascites, 28%; bowel obstruction, 12%; pleural effusion, 10%; bladder obstruction, 3%; and disordered nutrition that required support with parenteral nutrition, 9%. Patients may not always have received interventions for major complications; for example, pleural effusion apparently was left untreated in almost half of the women with this problem. After adjustment, women who died at younger ages were more likely to receive an intervention, compared to older women (odds ratio for each decade of age, 0.71, 95% confidence interval=0.53-0.94, P for trend=0.02). The study, which preceded the establishment of palliative care programs, suggests that care given to ovarian cancer patients at the end of life may be inadequate.

PMID: 17606360 [PubMed - as supplied by publisher]

Tuesday, July 03, 2007

Endometriosis Raises Risk Of Ovarian, Kidney And Thyroid Cancer



Endometriosis Raises Risk Of Ovarian, Kidney And Thyroid Cancer

The scientists found the endometriosis raised the risk of developing the following types of tumors:

-- Ovarian tumors - 37% greater risk
-- Endocrine tumors - 38% greater risk
-- Kidney tumors - 36% greater risk
-- Thyroid tumors - 33% greater risk
-- Brain tumors - 27% greater risk
-- Malignant melanoma - 23% greater risk
-- Breast cancer - 9% greater risk
Surprisingly, women with endometriosis seem to have a 29% lower risk of developing cervical cancer.

Saturday, June 30, 2007

Quality of Life for Patients With Epithelial Ovarian Cancer



Quality of Life for Patients With Epithelial Ovarian Cancer

Cancer genetic risk assessment for individuals at risk of familial breast cancer



Cancer genetic risk assessment for individuals at risk of familial breast cancer

Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families -- Chen et al. 110 (1): 18 -- Obstetrics & Gynecolo



Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families -- Chen et al. 110 (1): 18 -- Obstetrics & Gynecology

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations -- Kadouri et al. 44 (7): 467 -- Journal of Medical Genetics



Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations -- Kadouri et al. 44 (7): 467 -- Journal of Medical Genetics

2007 Timing of Referral to Hospice and Quality of Care: Length of Stay and Bereaved Family Members' Perceptions of the Timing of Hospice Referral



JPSM_Late-Referrals_2007.pdf (application/pdf Object)

Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer -- Mutch et



Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer -- Mutch et al. 25 (19): 2811 -- Journal of Clinical Oncology

Friday, June 29, 2007

Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy -- Tac



Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy -- Tacca et al. 12 (6): 636 -- The Oncologist

Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial -- Charu e



Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial -- Charu et al. 12 (6): 727 -- The Oncologist

Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector -- Kouvaris et al. 12 (6): 738 -- The Oncologist



Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector -- Kouvaris et al. 12 (6): 738 -- The Oncologist

Gynecologic Oncology : Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma



ScienceDirect - Gynecologic Oncology : Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

Gynecologic Oncology : Defining practice patterns in Gynecologic Oncology to prevent pulmonary embolism and deep venous thrombosis



ScienceDirect - Gynecologic Oncology : Defining practice patterns in Gynecologic Oncology to prevent pulmonary embolism and deep venous thrombosis

Gynecologic Oncology : A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-ter



ScienceDirect - Gynecologic Oncology : A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model

Saturday, June 16, 2007

Wednesday, June 06, 2007

Is Telik Insane?



Is Telik Insane?

ICON7 : A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial



ICON7 : A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial

Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Meno



Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Meno

2007 Abstract Study of symptoms in terminally ill patients with ovarian carcinoma



HighWire Press -- Medline Abstract

2007 Telik Reports Cancer Patients Die Sooner on Its Drug - Telcyta



Bloomberg.com: Worldwide

Should healthcare providers have a duty to warn family members of individuals with an HNPCC-causing mutation? A survey of patients from the Ontario Fa



Should healthcare providers have a duty to warn family members of individuals with an HNPCC-causing mutation? A survey of patients from the Ontario Familial Colon Cancer Registry -- Kohut et al. 44 (6): 404 -- Journal of Medical Genetics

2Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) -- Vasen et al. 44 (6): 353 -- Journal of Medical Genetics



Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) -- Vasen et al. 44 (6): 353 -- Journal of Medical Genetics

Table 2 Lifetime risk of cancer reported in families with an identified mismatch repair mutation

Colorectal cancer (men) 28–75%
Colorectal cancer (women) 24–52%
Endometrial cancer 27–71%
Ovarian cancer 3–13%
Gastric cancer 2–13%
Urinary tract cancer 1–12%
Brain tumour 1–4%
Bile duct/gallbladder cancer 2%
Small-bowel cancer 4–7%

2007 Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer - Mount Sinai



Exogenous hormones and colorectal cancer risk in C...[Cancer Causes Control. 2007] - PubMed Result

Saturday, June 02, 2007

Health Affairs Blog - Patient Safety



The bottom line, according to Groopman, is that doctors often don’t ask the right questions and don’t listen carefully enough when the patient answers. Expect to hear more about this. The blogs are already buzzing.


Health Affairs Blog: "The bottom line, according to Groopman, is that doctors often don’t ask the right questions and don’t listen carefully enough when the patient answers. Expect to hear more about this. The blogs are already buzzing."

Saturday, May 12, 2007

Int J Gynecol Cance (Article Abstract) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front line treatment of ovarian cancer



Blackwell Synergy - Int J Gynecol Cancer, Volume 17 Issue 3 Page 561 - May/June 2007 (Article Abstract)

Int J Gynecol Cancer (Article Abstract)



Blackwell Synergy - Int J Gynecol Cancer, Volume 17 Issue 3 Page 557 - May/June 2007 (Article Abstract): "International Journal of Gynecological Cancer


Professionals’ and patients’ views of routine follow-up: a questionnaire survey
International Journal of Gynecological Cancer 17 (3), 557–560.
doi:10.1111/j.1525-1438.2007.00839.x


* F.M. KEW**Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, EnglandFiona M. Kew, MB, ChB, MRCOG, Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Sheriff Hill, Gateshead, Tyne and Wear NE9 6SX, England. Email: fiona.kew@ghnt.nhs.uk,
* K. GALAAL**Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, England,
* H. MANDERVILLE**Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, England &
* L. VERLEYE**Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, England

*Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, England


Abstract

Traditionally, women who have been treated for a gynecological cancer have undergone long-term follow-up by hospital doctors. Recently, there has been interest in alternative models of follow-up, including nurse-based review. The project compares patients’ and professionals’ views of follow-up. A questionnaire was completed by 96 women attending routine follow-up clinics and by 32 professionals involved in delivering follow-up. A large majority of women (82/96, 92%) and professionals (25/34, 73%) thought that follow-up should be provided by a hospital doctor. However, professionals were more likely to think that specialist nurses and general practitioners should be involved in the provision of follow-up (P < 0.01). Professionals thought that the most important part of the follow-up visit was the consultation, whereas women thought it was the examination (P < 0.001). Women thought that detection of recurrence was the most important reason for continuing surveillance, whereas professionals regarded addressing patients’ concerns as the primary reason for follow-up (P < 0.001). We conclude that the views of women undergoing follow-up after gynecological cancer differ significantly from the professionals providing follow-up care. These views must be considered when developing alternative follow-up strategies.

Living Lessons®: Increasing awareness of hospice palliative care in Canada



Living Lessons®: Increasing awareness of hospice palliative care in Canada

2007 abstract: Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs



Entrez PubMed

Pain Management in Hospitalized Cancer Patients: A Systematic Review -- Goldberg and Morrison 25 (13): 1792 -- Journal of Clinical Oncology



Pain Management in Hospitalized Cancer Patients: A Systematic Review -- Goldberg and Morrison 25 (13): 1792 -- Journal of Clinical Oncology

2007 UK abstract: The research priorities of patients attending UK cancer treatment centres: finding from a modified nominal group study



Entrez PubMed

Br J Cancer. 2007 Mar 26;96(6):875-81. Epub 2007 Mar 6.Click here to read Links
The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study.

* Corner J,
* Wright D,
* Hopkinson J,
* Gunaratnam Y,
* McDonald JW,
* Foster C.

School of Nursing and Midwifery, University of Southampton, Southampton SO17 1BJ, UK.

Members of the public are increasingly consulted over health care and research priorities. Patient involvement in determining cancer research priorities, however, has remained underdeveloped. This paper presents the findings of the first consultation to be conducted with UK cancer patients concerning research priorities. The study adopted a participatory approach using a collaborative model that sought joint ownership of the study with people affected by cancer. An exploratory, qualitative approach was used. Consultation groups were the main method, combining focus group and nominal group techniques. Seventeen groups were held with a total of 105 patients broadly representative of the UK cancer population. Fifteen areas for research were identified. Top priority areas included the impact cancer has on life, how to live with cancer and related support issues; risk factors and causes of cancer; early detection and prevention. Although biological and treatment related aspects of science were identified as important, patients rated the management of practical, social and emotional issues as a higher priority. There is a mismatch between the research priorities identified by participants and the current UK research portfolio. Current research activity should be broadened to reflect the priorities of people affected by the disease.

PMID: 17342090 [PubMed - indexed for MEDLINE]

2007 March - Clinical Care Options Oncology - Management of Recurrent Epithelial Ovarian Cancer: Current Standards and Novel Approaches (slide set)



Clinical Care Options Oncology - Management of Recurrent Epithelial Ovarian Cancer: Current Standards and Novel Approaches

Thursday, April 19, 2007

April 19th, 2007 - message from New York reported event Friday April 20th - 10-12:30 pm Central Park at West 67th St, NY



I'm a reporter at New York Magazine, and we're organizing a big photo shoot
in Central Park TOMORROW.
I'm hoping that you could post it on your blog, and maybe even attend the
shoot yourself, if you live in the NY area! We're really working hard to
find just another 40 people to
come, and time is running out!

All the best,
Katie Charles
212 508 0668


New York Magazine Cover Shoot

New York Magazine is currently working on a very important feature story
about New Yorkers living with cancer. For a potential cover, we would like
to gather 300-350 New Yorkers living with cancer or in remission, in one
place, for an incredibly positive & moving picture. We are looking for
people of all ages, and of all races to to be photographed together.

We want to show the unity of the fight, so we are asking everyone to dress
on their own, as they normally would- no organization specific t-shirts. We
want the picture to look like a beautiful group of wildflowers. We hope this
will help raise awareness & funding for all.

Any interested participants should contact me directly at
alex_pollack@newyorkmag.com.
Logistical info below:

FINAL CALL SHEET/NEW YORKERS LIVING WITH CANCER

Date: Friday April 20th, 2007
Time: 10AM-12:30PM
Check-In Location: Tavern on the Green, Central Park at West
67th Street
Phone: 212.873.3200
New York Magazine contacts: Katie Charles 202.368.1836; Alex Pollack
917.538.1054

*Map attached
**IMPORTANT: Please arrive on time, as we have a very narrow window for the
permit from the Parks Department.

Let¹s try to have some color even though spring is late. Please dress in the
brightest color coat that you have- we don¹t want everyone in black or navy
coats, or the picture will look dreary. Please bring minimal bags/stuff with
you so we don¹t add unnecessary clutter to the photo. You will be asked to
fill out the attached 2 page form at the check-in table at Tavern on the
Green. To expedite the check-in process, if you are able to fill out the
form, print it & bring it with you, it would be very helpful. We will be
making individual portraits of each of you prior to the group shot.


IN CASE OF RAIN:
We have set up a rain date, should the weather not cooperate on Thursday
night/Friday. We have also set up a rain hotline. For updated information on
Friday morning, please call 212.508.0551.

Rain Date: Sunday April 22, 2007
Time: 11AM
Location: Pier 59 Studios, 59 Chelsea Piers
(btwn. 17th & 18th Streets on the water), Studio C

http://www.pier59studios.com/home.html
Phone: 212.691.5959


We¹re very excited to meet you all and to collaborate on this beautiful and
inspiring image.

Sincerely,
Katie Charles and Alex Pollack

Saturday, March 31, 2007

Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome (abstract)



European Journal of Obstetrics & Gynecology and Reproductive Biology

New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000



New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000

Canada - Best Practice & Research Clinical Obstetrics & Gynaecology : Patient safety in women's health-care: professional colleges can make a differe



ScienceDirect - Best Practice & Research Clinical Obstetrics & Gynaecology : Patient safety in women's health-care: professional colleges can make a difference. The Society of Obstetricians and Gynaecologists of Canada MOREOB program

Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy? -- Silber et al. 25 (10): 1169 -- Journal of Clinical Oncol



Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy? -- Silber et al. 25 (10): 1169 -- Journal of Clinical Oncology

Gynecologic Oncology or Medical Oncology: What's in a Name? -- Cannistra 25 (10): 1157 -- Journal of Clinical Oncology



Gynecologic Oncology or Medical Oncology: What's in a Name? -- Cannistra 25 (10): 1157 -- Journal of Clinical Oncology

Saturday, March 24, 2007

Gynecologic Oncology : A cost–effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian



ScienceDirect - Gynecologic Oncology : A cost–effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer:

"Conclusions.

Second-line chemotherapy is cost-effective for patients with platinum-sensitive recurrent EOC. Due to minimal improvements in overall survival, third- and fourth-line chemotherapy are not cost-effective strategies."

2007 abstract: What do primary care nurses and radiation therapists in a Canadian (Sunnybrook, Toronto) cancer centre think about clinical trials?



Entrez PubMed

From Cancer Patient to Cancer Survivor: Lost in Transition - Institute of Medicine



From Cancer Patient to Cancer Survivor: Lost in Transition - Institute of Medicine

Genentech: Avastin - Full Prescribing Information



Genentech: Avastin - Full Prescribing Information

Sandi's note: increased attention needs to be paid to nasal perforations ( Respiratory: nasal septum perforation) in patient populations

2007 abstract: The management of families affected by hereditary non-polyposis colorectal cancer (HNPCC/Lynch Syndrome)



IngentaConnect The management of families affected by hereditary non-polyposis c...

2007 Clinical Care Options Oncology - Management of Recurrent Epithelial Ovarian Cancer: Current Standards and Novel Approaches



Clinical Care Options Oncology - Management of Recurrent Epithelial Ovarian Cancer: Current Standards and Novel Approaches

Instructional - Intraperitoneal therapy in Ovarian Cancer



barrick_ip_instructional.pdf (application/pdf Object)

JAMA -- Abstract: Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome: A Systematic Review



JAMA -- Abstract: Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome: A Systematic Review, September 27, 2006, Lindor et al. 296 (12): 1507

CLINICIAN'S CORNER
Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome

A Systematic Review

Noralane M. Lindor, MD; Gloria M. Petersen, PhD; Donald W. Hadley, MS, CGC; Anita Y. Kinney, PhD; Susan Miesfeldt, MD; Karen H. Lu, MD; Patrick Lynch, MD; Wylie Burke, MD, PhD; Nancy Press, PhD

JAMA. 2006;296:1507-1517.

Context About 2% of all colorectal cancer occurs in the context of the autosomal dominantly inherited Lynch syndrome, which is due to mutations in mismatch repair genes. Potential risk-reducing interventions are recommended for individuals known to have these mutations.

Objectives To review cancer risks and data on screening efficacy in the context of Lynch syndrome (hereditary nonpolyposis colorectal cancer) and to provide recommendations for clinical management for affected families, based on available evidence and expert opinion.

Data Sources and Study Selection A systematic literature search using PubMed and the Cochrane Database of Systematic Reviews, reference list review of retrieved articles, manual searches of relevant articles, and direct communication with other researchers in the field. Search terms included hereditary non-polyposis colon cancer, Lynch syndrome, microsatellite instability, mismatch repair genes, and terms related to the biology of Lynch syndrome. Only peer-reviewed, full-text, English-language articles concerning human subjects published between January 1, 1996, and February 2006 were included. The US Preventive Services Task Force's 2-tier system was adapted to describe the quality of evidence and to assign strength to the recommendations for each guideline.

Evidence Synthesis The evidence supports colonoscopic surveillance for individuals with Lynch syndrome, although the optimal age at initiation and frequency of examinations is unresolved. Colonoscopy is recommended every 1 to 2 years starting at ages 20 to 25 years (age 30 years for those with MSH6 mutations), or 10 years younger than the youngest age of the person diagnosed in the family. While fully acknowledging absence of demonstrated efficacy, the following are also recommended annually: endometrial sampling and transvaginal ultrasound of the uterus and ovaries (ages 30-35 years); urinalysis with cytology (ages 25-35 years); history, examination, review of systems, education and genetic counseling regarding Lynch syndrome (age 21 years). Regular colonoscopy was favored for at-risk persons without colorectal neoplasia. For individuals who will undergo surgical resection of a colon cancer, subtotal colectomy is favored. Evidence supports the efficacy of prophylactic hysterectomy and oophorectomy.

Conclusions The past 10 years have seen major advances in the understanding of Lynch syndrome. Current recommendations regarding cancer screening and prevention require careful consultation between clinicians, clinical cancer genetic services, and well-informed patients.


Author Affiliations: Departments of Medical Genetics (Drs Lindor and Petersen) and Health Sciences Research (Dr Petersen), Mayo Clinic College of Medicine, Rochester, Minn; Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Md (Mr Hadley); Department of Medicine and Huntsman Cancer Institute, University of Utah, and Veterans Affairs Medical Center, Salt Lake City (Dr Kinney); Medical Oncology, Maine Center for Cancer Medicine and Blood Disorders and Maine Medical Center, Portland (Dr Miesfeldt); Departments of Gynecologic Oncology (Dr Lu) and Gastrointestinal Medicine and Nutrition (Dr Lynch), M. D. Anderson Cancer Center, University of Texas, Houston; Department of Medical History and Ethics, University of Washington, Seattle (Dr Burke); and Schools of Nursing and Medicine, Oregon Health and Science University, Portland (Dr Press).


RELATED ARTICLES

This Week in JAMA
JAMA. 2006;296:1437.
FULL TEXT

Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome
Judith Balmaña, David H. Stockwell, Ewout W. Steyerberg, Elena M. Stoffel, Amie M. Deffenbaugh, Julia E. Reid, Brian Ward, Thomas Scholl, Brant Hendrickson, John Tazelaar, Lynn Anne Burbidge, and Sapna Syngal
JAMA. 2006;296:1469-1478.
ABSTRACT | FULL TEXT

Prediction of Germline Mutations and Cancer Risk in the Lynch Syndrome
Sining Chen, Wenyi Wang, Shing Lee, Khedoudja Nafa, Johanna Lee, Kathy Romans, Patrice Watson, Stephen B. Gruber, David Euhus, Kenneth W. Kinzler, Jeremy Jass, Steven Gallinger, Noralane M. Lindor, Graham Casey, Nathan Ellis, Francis M. Giardiello, Kenneth Offit, Giovanni Parmigiani, and for the Colon Cancer Family Registry
JAMA. 2006;296:1479-1487.
ABSTRACT | FULL TEXT

Predicting and Preventing Hereditary Colorectal Cancer
James M. Ford and Alice S. Whittemore
JAMA. 2006;296:1521-1523.
EXTRACT | FULL TEXT

Colon Cancer
John L. Zeller, Cassio Lynm, and Richard M. Glass
JAMA. 2006;296:1552.
EXTRACT | FULL TEXT

Saturday, March 17, 2007

this is not a singular issue - as reported in the Toronto Star: "The Unkindest Cut"



Here is what this particular article today (link at the end of this note)
does not say with respect to other gynecologists all working in my own
area in the past few years:

1) Centenary Hospital (Scarborough, Ontario) vs Armstrong: case before
the courts (I am not aware if the courts have made their final decision
on this one):
Hansard:
http://www.canlii.org/eliisa/simpleSearch.do?language=en&requestOrigin=requestSimpleOrAdvanced&defaultQuery=armstrong+vs+centenary&queryMethod=allQuery&Search=Search
http://www.canlii.org/on/cas/onca/2005/2005onca10427.html

Armstrong v. Centenary Health Centre

Citation : 2002 CanLII 42546 (ON S.C.) Date: December 20, 2002
Language: en
Ontario > Superior Court of Justice

Armstrong v. Centenary Health Centre
Citation : 2005 CanLII 20712 (ON C.A.) Date: June 13, 2005 Language: en
Ontario > Court of Appeal for Ontario


2) Whitby (Ontario) obstetrician-gynecologist Dr. Errol Wai-Ping
http://www.cbc.ca/fifth/donoharm.html

3) Dr. Richard Neale, a gynecologist and obstetrician, who worked in
Durham Region (Ajax/Pickering) and was prohibited from practicing in
Ontario before
he returned to England. (note: his licence was taken away while
practicing in England)
http://www.cmaj.ca/cgi/content/full/163/5/584-a


4) Toronto obstetrician and gynecologist Dr. Richard Austin
http://www.thestar.com/printArticle/193080

_*The unkindest cut TheStar.com - News - The unkindest cut*_
March 17, 2007

TheStar.com - News - The unkindest cut



TheStar.com - News - The unkindest cut

Saturday, March 10, 2007

2007 SGO: Specialist Care Required for Ovarian Cancer - Dr Chan/California



SGO: Specialist Care Required for Ovarian Cancer - CME Teaching Brief® - MedPage Today

links to genetic databases: Memorial University of Newfoundland - Faculty of Medicine



Memorial University of Newfoundland - Faculty of Medicine

2007 A new varian database for mismatch repair genes associated with Lynch Syndrome: Memorial University of Newfoundland - Faculty of Medicine



Memorial University of Newfoundland - Faculty of Medicine
Hum Mutat. 2007 Mar 8
A new variant database for mismatch repair genes associated with Lynch syndrome.

* Woods MO,
* Williams P,
* Careen A,
* Edwards L,
* Bartlett S,
* McLaughlin JR,
* Younghusband HB.
Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.

Mutations in some mismatch repair (MMR) genes are associated with Lynch syndrome (LS; also called hereditary nonpolyposis colorectal cancer [HNPCC]), an autosomal dominant cancer susceptibility syndrome. Colorectal cancer (CRC) is the most frequent cancer observed in LS. However, tumors occur at a variety of extracolonic sites and individuals may have multiple primary cancers. LS is the most common hereditary form of CRC, accounting for approximately 1% of all CRC. Since the first account of mutations in MSH2 causing this cancer susceptibility syndrome in 1993, mutations in three additional MMR genes, MLH1, MSH6, and PMS2, have been shown to cause LS. More than 1,500 different variants have been identified in these four genes and approximately 80% of the alterations have been identified in MLH1 and MSH2. There have been a few previous attempts to systematically record MMR variants associated with LS patients; however, they were not complete nor were they continuously updated. Thus, it was our goal to generate and maintain a comprehensive catalogue of MMR variants from genes known to be mutated in LS (http://www.med.mun.ca/MMRvariants; last accessed 8 February 2007). Providing such a resource should aid investigators in understanding the significance of the variants. Hum Mutat 0, 1-5, 2007. (c) 2007 Wiley-Liss, Inc.

PMID: 17347989

Wednesday, February 21, 2007

NO RESPONSE BY DECISION-MAKERS - sad! Ovarian Advocate - Caelyx for British Columbia Ovarian Cancer Women - funding vs life



FYI - Re: http://www.ovarianadvocate.ca/



February 17th, 2007


Sandi Pniauskas
117 Glen Hill Drive
Whitby, Ontario, Canada
L1N6Z8

Dear Madam/Sirs;

Re: Funding Caelyx for Treatment of Recurrent Ovarian Cancer in British
Columbia

I am writing to appeal to you to ensure that Caelyx is funded as a
treatment for recurrent ovarian cancer, or as deemed necessary, through
patient/physician decision-making. I do this because I have compassion,
understanding and intimate knowledge of the issues which ovarian cancer
women, their families and their friends face. From the initial
pre-surgery consultations to the last breath our ovarian cancer women
take. Research for decades is proof positive that ovarian cancer is the
most lethal of all gynecologic cancers. And yet, how far have we
actually progressed? 'Lethal' today is still the word used to describe
ovarian cancer. And yet, with our lack of decision-making, we actually
in fact consider our ovarian cancer women to be dispensable. They
deserve every chance and in light of extensive research, which you have
already received, the underlying issue of lack of actual access is not
comprehensible to me. I don't believe that I need to educate you on the
evidence-based research which provides sufficient criteria for simply
funding this chemotherapy for ovarian cancer women - today.

Further, it is irresponsible to confuse the economies of providing
Caelyx to ovarian cancer women in need. Confusion - because it is with
the hopes of remission or extension of life which no economies can ever
truly value in concrete terms. Further, recent reports indicate that
B.C.'s coffers are flush with funds. It therefore is a matter of
morality and quite simply the ability of the decision-makers to actually
make this decision.

Let us not continue to make mistakes of the past. The disparities in
access to either life-saving or life-extending therapies across
Provinces are well known. As a matter of fact, in the late 1990's,
Canadian ovarian cancer women experienced the very same issue between
Quebec and Ontario. Taxol was accessible to ovarian cancer women in
Quebec, and not in Ontario. It seems we have not yet learned our lessons
and are repeating the same mistakes but at the sacrifice of the valuable
women in our lives. The obvious lesson is that ovarian cancer does not
care where you live, but your survival does. How sad, in fact, that
while Health Care Ministers, Provincially and at the Federal level
discuss these issues, we simply are unable to recognize the deaths - the
actual realities while we wait for decisions. This is not acceptable and
our ovarian cancer women cannot wait. More importantly, the system which
you represent, has failed these women. It is a moral issue and only a
moral issue which stands in the way of ovarian cancer women in British
Columbia having access to this particularly effective chemotherapy.

Since my ovarian cancer diagnosis in 1999, I have been in the very
fortunate situation of surviving. But this survival comes at a price. It
is and has been typically a short term friendship, but one of value,
which words defy. It is and has been their absolute strength and will to
live and, yes, to suffer in silence, that alone deserves our respect by
doing the 'right thing'. You have the ability to give my ovarian cancer
women friends in British Columbia the will and the ability to improve
their life. This is a 'gift' through really a few strokes of the pen.
You can fund Caelyx for our ovarian cancer women in British Columbia. We
cannot wait, we should not have to wait.



Thank you.

Sincerely,

Sandi Pniauskas
email: sandipn@sympatico.ca

Friday, January 26, 2007

2007 January: Sunnybrook cancels some cancer surgery



Sunnybrook cancels some cancer surgery

Globe and Mail - Toronto,Ontario,Canada
TORONTO -- Sunnybrook Health Sciences Centre is cancelling dozens of operations, including those of cancer patients....

2007 January: Health Minister Appoints Richard Ling (lawyer) as New Chair of Cancer Care Ontario



This sends a message.

2007 January: Wait times for cancer patients decreasing: report - Ontario - reference surgical waits Sunnybrook Regional Cancer Centre



".....Sunnybrook Health Sciences Centre is cancelling dozens of surgeries as it tries to deal with a patient backlog, and those waiting for cancer treatment...."

New Study Evaluates Communication About Chemotherapy-Induced Anemia and Fatigue in Clinical Settings



Amgen Launches 2007 Breakaway From Cancer Initiative - support/free services/programs - U.S.



2007 full text: Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort



2007 CIHI reports on length of stay for emergency department visits in Ontario



2007 Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome (Bristow/



2006 Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.



2007 abstract: 2007 Age at first birth and the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers



2007 University of Toronto: Faculty, student develop new ovarian cancer treatment (Jan 26/07)



2007 UK - 3rd annual conference: "Where's the Patient's Voice in Health Professional Education?"



An exceptional opportunity for patients/carers and healthcare professionals.

Sunday, December 31, 2006

Gastroenterology: Microsatellite Instability in Interval Colon Cancers (abstract)



Gastroenterology: "Microsatellite Instability in Interval Colon Cancers"

Right Drug, Right Patient, Right Now (comment: well, not exactly true)



Right Drug, Right Patient, Right Now — AskBig.: "Right Drug, Right Patient, Right Now"

The Scientist : "Silent" mutations are not always silent



The Scientist : "Silent" mutations are not always silent

2006 UK Safer Health Care: Relationship between patient complaints and surgical complications



ComplicationsAndComplaints.pdf (application/pdf Object)

Moral Priorities in a Teaching Hospital



Moral Priorities in a Teaching Hospital

Entrez PubMed



Entrez PubMed: "Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary."

Emerging Themes in Epidemiology | Full text | Identifying related cancer types based on their incidence among people with multiple cancers



Emerging Themes in Epidemiology | Full text | Identifying related cancer types based on their incidence among people with multiple cancers

2006 Waiting Your Turn - Fraser Institute



wyt2006.pdf (application/pdf Object)

Paying More Getting Less 2006 Fraser Institute



PayingMoreGettingLess2006.pdf (application/pdf Object)

Friday, December 22, 2006

2006 Treatment Issues in Clear Cell Carcinoma of the Ovary:



1089.pdf (application/pdf Object)

Moral Emotions and Moral Behavior - Annual Review of Psychology, 58(1):345 - Abstract



Moral Emotions and Moral Behavior - Annual Review of Psychology, 58(1):345 - Abstract

Minimizing delays in ovarian cancer diagnosis: an expansion of Andersen's model of 'total patient delay' -- Evans et al., 10.1093/fampra/cml063 -- Fam



Minimizing delays in ovarian cancer diagnosis: an expansion of Andersen's model of 'total patient delay' -- Evans et al., 10.1093/fampra/cml063 -- Family Practice

Google - Internet Over Internists? | theledger.com



Google - Internet Over Internists? | theledger.com

Pharmacologic opportunities for the chemoprevention of ovarian cancer. -- Rodriguez et al. 2006 (3): CS18-03 -- AACR Meeting Abstracts



Pharmacologic opportunities for the chemoprevention of ovarian cancer. -- Rodriguez et al. 2006 (3): CS18-03 -- AACR Meeting Abstracts

FDA Proposes Rules Overhaul to Expand Availability of Experimental Drugs



FDA Proposes Rules Overhaul to Expand Availability of Experimental Drugs

NCI Cancer Bulletin for December 12, 2006 (HTML) - National Cancer Institute



NCI Cancer Bulletin for December 12, 2006 (HTML) - National Cancer Institute

Entrez PubMed



Entrez PubMed

Entrez PubMed



Entrez PubMed

Friday, December 01, 2006

CancerWise - December 2006 - Trial Studies Ovarian Cancer Screening Test



CancerWise - December 2006 - Trial Studies Ovarian Cancer Screening Test

Trial Studies Ovarian Cancer Screening Test
Healthy Postmenopausal Women Being Recruited

Should women be screened for ovarian cancer? Researchers hope to answer that question through a new study in which blood and urine samples from healthy, postmenopausal women are collected and analyzed.

Goal of study

M. D. Anderson researchers conducting the Low-Risk Ovarian Cancer Study hope the clinical trial and others like it one day may lead to a more effective screening test to increase early detection of the disease.

“Unfortunately, there’s no effective screening test, like the mammogram or colonoscopy, to detect ovarian cancer at an early stage when the chance of cure is greatest,” says Karen Lu, M.D., associate professor in M. D. Anderson’s Department of Gynecologic Oncology. “As a result, more than two-thirds of all ovarian cancers are found at an advanced stage.”

The purpose of the study is to not only evaluate a blood marker called CA-125 over a period of time, but also to create new markers for ovarian cancer detection. Urine also will be collected so that its proteins can be used to help create new markers.

Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings -- Connor and McDiarmid 56 (6): 354 -- CA: A Cancer Journal for Clin



Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings -- Connor and McDiarmid 56 (6): 354 -- CA: A Cancer Journal for Clinicians

ScienceDirect - Gynecologic Oncology : Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?



ScienceDirect - Gynecologic Oncology : Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?

ScienceDirect - Gynecologic Oncology : Long-term outcomes following conservative surgery for borderline tumor of the ovary: A large population-based s



ScienceDirect - Gynecologic Oncology : Long-term outcomes following conservative surgery for borderline tumor of the ovary: A large population-based study

ScienceDirect - Gynecologic Oncology : Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer



ScienceDirect - Gynecologic Oncology : Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer

ScienceDirect - Gynecologic Oncology : Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial pr



ScienceDirect - Gynecologic Oncology : Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study: "Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study"

2006 The Epidemiology of Second Primary Cancers



1055-9965.EPI-06-0414v1.pdf (application/pdf Object)

Resource and Time Commitment of Treating Anemia in Cancer Patients



Resource and Time Commitment of Treating Anemia in Cancer Patients

Whose Opinion Counts? -- Loprinzi et al. 24 (33): 5183 -- Journal of Clinical Oncology



Whose Opinion Counts? -- Loprinzi et al. 24 (33): 5183 -- Journal of Clinical Oncology

Thursday, November 23, 2006

BBC NEWS | Health | Herceptin costs 'threaten care'



BBC NEWS | Health | Herceptin costs 'threaten care'

How much will Herceptin really cost? -- Barrett et al. 333 (7578): 1118 -- BMJ



How much will Herceptin really cost? -- Barrett et al. 333 (7578): 1118 -- BMJ: "So we could fund Herceptin if we did not treat 355 patients receiving adjuvant treatment (16 of whom would be cured) or 208 patients receiving palliative chemotherapy, and if we found �0.5m from another source. These untreated patients will be people we know. We will be the ones to tell them they are not getting a treatment that has been proved to be effective, which costs relatively little, because it is not the 'treatment of the moment.'"

Newswise | Physicians Rate Involvement in Public Roles as Important



Newswise | Physicians Rate Involvement in Public Roles as Important

Curing Healthcare: How to get the public involved in transforming our healthcare system



Curing Healthcare: How to get the public involved in transforming our healthcare system

Canada gets poor marks in international health survey of doctors



Canada gets poor marks in international health survey of doctors

Entrez PubMed



Entrez PubMed: "Clinical characteristics of patients with sporadic colorectal cancer and primary cancers of other organs"

Trends in physician supply -- Kondro 175 (11): 1362 -- Canadian Medical Association Journal



Trends in physician supply -- Kondro 175 (11): 1362 -- Canadian Medical Association Journal

Cancer hurts caregivers, too - USATODAY.com



Cancer hurts caregivers, too - USATODAY.com

Resource and Time Commitment of Treating Anemia in Cancer Patients



Resource and Time Commitment of Treating Anemia in Cancer Patients

A Survey of Neurologists on Bothersome Patient Behaviors



A Survey of Neurologists on Bothersome Patient Behaviors

Monday, November 20, 2006

2006 November - Cancer - Our National Shame - The killing cost of drug treatment



globeandmail.com: The killing cost of drug treatment

http://tinyurl.com/ykrl7s

Cancer: Our national shame
The killing cost of drug treatment
For a health-care system based on the principle of equal access, the reality is tragically different